Literature DB >> 1059500

Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia.

H J Lawrence, J Simone, R J Aur.   

Abstract

The records of 314 children with acute lymphocytic leukemia (ALL) were reviewed to determine the frequency, clinical and laboratory features; contributing factors; and prognosis of cyclophosphamide-induced hemorrhagic cystitis. Twenty-five well-documented cases of hemorrhagic cystitis were identified. While most of the affected children suffered a mild transient illness, 1 patient died as a result of bladder hemorrhage. The doses of cyclophosphamide received by these children ranged widely and did not correlate with the severity of the cystitis. The frequency of this complication did not differ significantly with sex, age or route of administration. However, cystitis was over twice as frequent in black children as in white. Nineteen of 25 cases occurred in the spring and summer months. The group of affected children did not differ significantly from a matched control group in terms of total drug dosage received, incidence of systemic toxicity, mean urine specific gravity, or overall survival.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1059500     DOI: 10.1002/1097-0142(197511)36:5<1572::aid-cncr2820360506>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

2.  Diagnostically challenging cases: what are atypia and dysplasia?

Authors:  Joseph Sanfrancesco; J Stephen Jones; Donna E Hansel
Journal:  Urol Clin North Am       Date:  2013-02-26       Impact factor: 2.241

Review 3.  Evidence-Based Practice Recommendations for Hydration in Children and Adolescents With Cancer Receiving Intravenous Cyclophosphamide.

Authors:  Deborah Robinson; Ginny Schulz; Rachel Langley; Kevin Donze; Kari Winchester; Cheryl Rodgers
Journal:  J Pediatr Oncol Nurs       Date:  2014-05-05       Impact factor: 1.636

4.  Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit.

Authors:  J A Murray
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-05

5.  General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade—a single-center retrospective study.

Authors:  Juan Li; Guowei Dai; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2014-07-23       Impact factor: 2.980

Review 6.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

Review 7.  Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer.

Authors:  A Lopez-Beltran; R J Luque; R Mazzucchelli; M Scarpelli; R Montironi
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.